CAMBRIDGE, Mass., Oct. 14, 2008 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that new data from several preclinical studies evaluating the company's innovative small molecule drug candidates -- oral Hsp90 inhibitor IPI-493 and oral Hedgehog signaling pathway inhibitor IPI-926 -- will be presented during the 20th AACR-EORTC-NCI Symposium on "Molecular Targets and Cancer Therapeutics," being held in Geneva, Switzerland from October 21 through October 24, 2008.
